In the present study all compounds AZD2281 molecular weight were treated as neutral and therefore regional differences in the intestinal pH, which are accounted for in the ADAM model, did not affect intestinal solubility

of the compounds. This may in particular lead to an overestimation of colonic solubility of basic compounds, whereas an opposite situation can occur for acidic compounds, for which the solubility is higher in the upper regions of the GI tract. There are also many in vivo factors that might contribute to the possible under/overestimation of drug dissolution and solubility within the GI tract. For instance the over-simplified composition of the small intestinal and colonic fluids in available PBPK absorption models, as well as the actual fluid volumes available to dissolve the drug might affect such estimations ( Sjogren et al., 2014). Furthermore, several biopharmaceutical and physicochemical properties, known to influence drug absorption, were not taken into account in this study, i.e. particle size and its distribution; excipients; and in particular the drug release mechanism, which was oversimplified in this study; just to name a few

(Martinez and Amidon, 2002). Consideration of such factors would have significantly increased the number of simulations to be performed, thus Z-VAD-FMK mw complicating any subsequent analysis. Those simulations were out of the scope of this work. One of the main goals of this work was to identify the parameter space in which a drug, formulated as CR, would display higher relative bioavailability than the corresponding IR formulation. The above results clearly indicated absorption – fa – to be reduced for all the CR formulation as compared to the IR formulations. Still, in the case of the simulated CYP3A4 substrates, the reduction in fa seemed to be compensated by an increase in FG ( Figs. 3B and S1B–S3B), that is, a reduction in the CYP3A4-mediated first pass intestinal metabolism. For some of the simulated compounds, this compensation was translated into similar exposure levels of CR formulations as compared to IR. The Bay 11-7085 proposed explanation is based on

the distribution of the CYP3A abundance along the GI tract. As discussed previously in this manuscript, the CYP3A enzymes decrease towards the distal regions of the human GI tract ( Berggren et al., 2007, Paine et al., 1997 and Zhang et al., 1999), this pattern is taken into account in the ADAM model. As a result, when a CR formulation releases its drug content into the distal regions of the intestine, the drug would encounter less CYP3A enzymes on its way towards the portal circulation, thus reducing the CYP3A-mediated intestinal first pass metabolism. In this study the impact on the AUC was however only noticeable for highly permeable (BCS classes 1 or 2) and highly cleared drugs (CLint,CYP3A4 ⩾ 250 μL/min/mg).